Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
OHSU Knight Cancer Institute
Eastern Cooperative Oncology Group
Global BioClinical
University of Southern California
University of Southern California
M.D. Anderson Cancer Center